Phio Pharmaceuticals to meet investors at H.C. Wainwright conference

Phio Pharmaceuticals will send senior executives to the H.C. Wainwright 28th Annual Global Investment Conference in New York City from Sept. 14-16 to meet with investors and outline progress on its lead cancer candidate, PH-762. The appearance gives the company a chance to update the market on its development plans as it works to advance its INTASYL-based program.

Why it matters: - Phio Pharmaceuticals is using a major investor conference to spotlight PH-762, its lead clinical program, and to reinforce the company’s development strategy. - The meetings come as the biotechnology company looks to sustain momentum around its INTASYL siRNA gene-silencing platform and its potential use in skin cancer.

What happened: - Phio Pharmaceuticals Corp. said members of its management team will hold one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference. - The conference runs Sept. 14-16, 2026, at the Lotte New York Palace Hotel in New York City. - President and CEO Robert Bitterman and CFO Lisa Carson will meet with investors during the event. - Management plans to discuss PH-762, strategic priorities and upcoming initiatives.

The details: - Phio Pharmaceuticals is a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL siRNA gene-silencing technology. - PH-762 is the company’s lead clinical development program. - PH-762 silences the PD-1 gene, which is implicated in several forms of skin cancer. - The Phase 1b trial for PH-762, identified as NCT# 06014086, evaluated the candidate for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. - The company describes PH-762 as a potential non-surgical treatment for skin cancers. - A webcast of Phio Pharmaceuticals’ presentation is available through the following link: Journey - Phio Pharmaceuticals also said it is a B2i Digital Featured Company and pointed investors to its in-depth profile at More information. - The company provided its website as phiopharma.com.

Between the lines: - The conference appearance suggests Phio Pharmaceuticals wants to keep investors focused on pipeline progress while it advances the next stage of PH-762 development. - The release also emphasizes long-term value creation, signaling that management sees investor communication as part of the clinical and financing roadmap. - The company included extensive forward-looking language around FDA interactions, trial planning and timing, underscoring that PH-762 remains in a development phase with execution risk.

What’s next: - Phio Pharmaceuticals is expected to use the conference to provide updated discussion around PH-762 and its broader clinical strategy. - The release says activities supporting the next phase of PH-762 clinical development are expected to be completed during the first quarter of 2027, subject to the risks outlined in the company’s filings. - Future progress will likely depend on FDA interactions, clinical development execution and financing conditions.

The bottom line: - Phio Pharmaceuticals is taking its lead cancer program to a key investor venue, aiming to translate early clinical development progress into broader market attention.